The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: Mechanistic implications for clinical medicine

Patrick K. Davis; Harsha Musunuru; Mark Walsh; Raman Mitra; Victoria Ploplis; Francis J. Castellino

doi:10.1160/TH12-04-0222

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2012; 108(03): 586-588
DOI: 10.1160/TH12-04-0222

Letters to the Editor

Schattauer GmbH

The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: Mechanistic implications for clinical medicine

Patrick K. Davis

¹W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

,

Harsha Musunuru

¹W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

,

Mark Walsh

¹W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

²Department of Emergency Medicine, Memorial Hospital of South Bend, Indiana, USA

,

Raman Mitra

³Memorial Advanced Cardiovascular Institute, South Bend, Indiana, USA

,

Victoria Ploplis

¹W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

,

Francis J. Castellino

¹W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, USA

References
1 Blech S, Ebner T, Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, Dabigatran in humans. DMD 2008; 36: 386-399.
2 Connelly S, Ezekowitz M, Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3 Stangier J, Rathgen K, Stähle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Pharmacol 2007; 64: 292-303.
4 Cotton B, McCarthy J, Holcomb J. Acutely injured patients on dabigatran. N Engl J Med 2011; 365: 2039-2040.
5 Zhou W, Schwarting S, Illanes S. et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke 2011; 42: 3594-3599.
6 van Ryn J, Stangier J, Haertter S. et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-1127.
7 Eerenberg E, Kamphuisen P, Sijpkens M. et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects. Circulation 2011; 124: 1573-1579.
8 Warkenton T, Margetts P, Connolley S. et al. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174.
9 Pezold M, Moore EE, Wohlauer MV. et al. Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes. Surgery 2012; 151: 48-54.
10 Carroll RC, Craft RM, Langdon RL. et al. Early evaluation of acute traumatic coagulopathy by thromboelastography. Transl Res 2009; 154: 34-39.
11 Enriquez LJ, Shore-Lesserson L. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth 2009; 103: i14-22.
12 Wohlauer M, Moore E, Thomas S. et al. Early platelet dysfunction: An unrecognized role in the acute co-agulopathy of trauma. J Am Coll Surg. 2012 in press.
13 Kashuk JL, Moore EE, Sawyer M. et al. Postinjury coagulopathy management: Goal directed resuscitation via POC thromboelastography. Ann Surg 2010; 251: 604-614.
14 Lew WK, Weaver FA. Clinical use of thrombin as a surgical hemostat. Biologics 2008; 02: 593-599.